Cushion the November 2026 LDC graduation shock before EU EBA, India DFTP, and pharma TRIPS waivers expire

Diagnosis

The curated note fixes the shock precisely: a November 2026 transition out of least developed country status that simultaneously removes three preferences Bangladesh's export economy was built on. It loses EU Everything But Arms (EBA) duty free access, India's Duty Free Tariff Preference (DFTP) scheme, and the pharmaceutical TRIPS waiver that let domestic producers make patented medicines without licensing fees. This is a labor problem first, which is why the lead body is the Ministry of Labour and Employment (MoLE). When tariff walls reappear at EU and Indian borders, the margin compression lands on the most labor intensive export, ready made garments, and the workers in it. The pharma waiver loss is a slower but parallel squeeze on a second employment base. The transition date is months away, the preferences switch off close to all at once, and there is no automatic replacement, so the window to soften the blow is now and it is short.

Recommended actions

1. Lock in EU GSP+ eligibility filings. Owner: Ministry of Commerce (with MoLE on the labor conventions). Mechanism: file the EU GSP+ application package, anchored on ratification and demonstrated implementation of the ILO core labor conventions that MoLE administers, so EBA does not lapse into the standard GSP tariff. Signal it is working: EU acknowledgment of a complete application and no gap between EBA expiry and GSP+ entry.
2. Stand up an export worker transition fund. Owner: MoLE, with a dedicated budget line. Mechanism: a wage support and reskilling facility for garment and pharma workers in factories that document order or margin loss tied to the preference withdrawal, disbursed through the existing labor administration rather than a new agency. Signal: enrolled workers and factories drawing from the line, and a falling rate of unmanaged layoffs in the affected districts.
3. Activate overseas employment as a pressure valve. Owner: Ministry of Expatriates' Welfare and Overseas Employment, with the Bureau of Manpower, Employment and Training (BMET). Mechanism: expand BMET skills certification and deployment channels so displaced export workers have a regulated migration pathway instead of distress migration. Signal: rising certified placements from affected sectors and districts.
4. Negotiate an India bilateral transition arrangement. Owner: Ministry of Commerce. Mechanism: open talks toward a bilateral trade arrangement that preserves DFTP era access on key lines, using the November date as the deadline that forces the schedule. Signal: a signed or initialed framework before the transition, or a standstill on tariff lines that matter most for jobs.
5. Protect the domestic pharma base. Owner: Ministry of Commerce and the drug regulator. Mechanism: a phased licensing and local production strategy for the molecules most exposed by the TRIPS waiver loss, so capacity and the jobs attached to it are not abandoned. Signal: maintained domestic production volumes on priority medicines through the transition.

Sequencing (first 12 months)

Do the GSP+ filing first: it has the longest external lead time and it unlocks the labor conventions that MoLE controls, so progress on conventions feeds the application directly. In parallel, MoLE creates the transition fund budget line, because a credible safety net is what lets the government hold a firm negotiating posture with the EU and India without fearing immediate domestic fallout. The India arrangement and the pharma strategy run next, both racing the November date. The BMET deployment channel can be expanded throughout and absorbs whatever displacement the other tracks fail to prevent.

Risks and constraints

The binding constraint is the calendar: the November 2026 transition is fixed and the preferences fall away together, so any track that slips past it leaves workers exposed with no fallback. GSP+ depends on a counterparty timeline Bangladesh does not control and on genuine, not paper, labor convention compliance, which MoLE cannot fake. The fiscal constraint is real: a transition fund competes for budget space, and underfunding it makes it theater. The India arrangement requires a willing partner. Spreading effort across all fronts risks doing none well, so the GSP+ and the safety net are the two that cannot fail.

Bottom line

Three preferences (EU EBA, India DFTP, the pharma TRIPS waiver) expire together at the November 2026 transition, and the cost falls on export workers, which is why MoLE leads. Secure GSP+ continuity and a funded worker transition line first, race an India arrangement and a pharma plan against the date, and keep BMET migration channels open as the relief valve.